Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2-breast cancer
Han, H. S. Lorusso, P. Hamilton, E. P. Martinez-JaƱez, N. Boni, V. Sanchez-Bayona, R. Palmieri, C. Armstrong, A. C. Fontana, E. Fisher, G.
Han, H. S.
Lorusso, P.
Hamilton, E. P.
Martinez-JaƱez, N.
Boni, V.
Sanchez-Bayona, R.
Palmieri, C.
Armstrong, A. C.
Fontana, E.
Fisher, G.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Han HS, Lorusso P, Hamilton EP, Martinez-JaƱez N, Boni V, Sanchez-Bayona R, et al. Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2-breast cancer. JOURNAL OF CLINICAL ONCOLOGY. 2025 JUN 1;43(16_SUPPL):1057-. PubMed PMID: WOS:001509259400001. English.